ONE PROVEN PORTFOLIO OF TESTS & SERVICES. THAT'S OUR FOUNDATION.

FOUNDATIONONE®CDx FOUNDATIONONE®LIQUID FOUNDATIONONE®HEME

Most experience with comprehensive genomic profiling*

>400 peer-reviewed publications on the current and potential utility of comprehensive genomic profiling

>350K patients tested with comprehensive genomic profiling in a clinical setting[1]

* As defined by the number of cancer patients tested by Foundation Medicine in a clinical setting with comprehensive genomic profiling and the amount of evidence published by Foundation Medicine in a research setting about comprehensive genomic profiling

FoundationOne®CDx is the first and only FDA-approved broad companion diagnostic for all solid tumors

All Foundation Medicine comprehensive genomic profiling tests:

CAP Accredited

New York State Department of Health (NYSDOH) Approved

CLIA Certified

Understanding the results:

- Medical Case Consulting by a team of oncologists and pathologists to discuss results
- Molecular Tumor Boards for eligible institutions to educate on the actionability of comprehensive genomic profiling

Workflow integration:

- Digital Experience for ordering, tracking and reporting
- EMR interfacing

Clinical trial matching:

- Notify physicians of enrollment opportunities for NCI-match trial arms
- Precision Enrollment program identifies patients with rare or specific biomarkers and matches them with sponsor trials using the FoundationSmartTrials™ engine

Patient Financial Support:

- Medicare and TRICARE cover FoundationOne®CDx for qualifying patients[2]
- Commercial payers, such as Cigna and many Blue Cross Blue Shield plans, offer coverage for Foundation Medicine testing services[3]
- Financial assistance is available for patients based on need and can be applied for at any point during the testing process

FOUNDATION MEDICINE

SEE OUR PROVEN PORTFOLIO OF TESTS ON THE BACK

Our Proven Portfolio

FOUNDATIONONE®CDx • First and only FDA-approved broad comparison diagnostic for all solid tumors • Indicated for 19 targeted therapies • Option to reflex to liquid	324 Genes (DNA), TMB + MSI + LOH*	FFPE Tissue (10 USS or 1 Block† + 1 H&E Slide)	<2 weeks††
FOUNDATIONONE®LIQUID • A laboratory developed test for all solid tumors • Longitudinal tracking	70 Genes (DNA), Reports MSI-H status	Peripheral Whole Blood (2 8.5mL Tubes)	<2 weeks††
FOUNDATIONONE®HEME • A laboratory developed test for hematologic malignancies, sarcomas or solid tumors where known or novel gene fusion detection is desired	406 genes (DNA), 265 genes (RNA), TMB + MSI	FFPE Tissue, Bone Marrow Aspirate, Peripheral Whole Blood (16 USS + 1 H&E or 1 FFPE block or 2.5 mL Bone Marrow Aspirate or 1 filled EDTA Tube + 2.5 mL Paxgene Tube Peripheral Whole Blood)	<2 weeks††
IHC • FDA-approved CDx for 2 immunotherapies in specific solid tumors	PD-L1	FFPE Tissue - 4 USS	5 days**

Learn more about our proven portfolio of tests and services at *www.foundationmedicine.com*

1. Unique patient profiles tested by Foundation Medicine and in Foundation Medicine database as of January 2020
2. Medicare and Medicare Advantage members have coverage of FoundationOne CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria. TRICARE members have coverage for FoundationOne CDx pursuant to TRICARE's medical policy and patient benefit plans.
3. All commercial payer coverage is pursuant to the applicable payer's medical policy and specific patient benefit plans. Foundation Medicine's FoundationOne Heme and FoundationOne Liquid tests have limited commercial payer coverage.

*For ovarian cancer
††Block is preferred
**From receipt of specimen

FoundationOne CDx is the only FDA-approved in vitro diagnostic test by Foundation Medicine. FoundationOne Liquid and FoundationOne Heme were developed and their performance characteristics determined by Foundation Medicine. They have not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed tests (LDTs) please see their respective Technical Specifications at www.foundationmedicine.com.

FoundationOne®CDx is a next-generation sequencing based in vitro test intended for use by healthcare professionals for advanced cancer patients with solid tumors. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is FDA-approved as a companion diagnostic to identify patients who may benefit from treatment with a specific list of therapies (listed in Table 1 in the Technical Information at www.foundationmedicine.com/f1cdx) in accordance with the approved therapeutic product labeling. Additional genomic findings, other than those listed in Table 1, may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment or clinical trial option, or that all relevant alterations will be detected. Some patients may require a biopsy. For the complete label, including important risk information, please visit www.foundationmedicine.com/f1cdx.

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | MKT-0361-01

FOUNDATION MEDICINE®